文献速递心外重症与机械循环支持

开胸入路成本分析:LATERAL试验的经济学结果

Cost of Thoracotomy Approach: An Analysis of the LATERAL Trial.
PubMed 文献 · Ann Thorac Surg · 2020-03-26

基于LATERAL临床试验同步收集的UB-04表单,分析经开胸入路植入HeartWare离心流左心室辅助装置(HVAD)的索引住院成本,并与同期Medicare数据(假定以传统胸骨正中切开为主)比较。结果显示开胸入路患者平均总索引住院成本为204,107美元/例,较胸骨正中切开组降低21.6%(P < .001),每例节省56,385美元,且几乎各成本类别均更低。

要点

  • 开胸入路植入HVAD的索引住院成本较胸骨正中切开每例节省56,385美元。
  • 开胸入路平均总索引住院成本为204,107美元/例,降低21.6%(P < .001)。
  • 开胸入路在几乎所有成本类别中均低于胸骨正中切开。

核心结论

  • 经开胸入路植入HVAD的索引住院成本低于同期Medicare数据所代表的传统胸骨正中切开入路。

研究设计与样本

  • LATERAL临床试验评估开胸入路植入HVAD的安全性和有效性,同步收集UB-04表单分析索引住院成本,并与2015-2016年Medicare成本数据比较。

主要发现

  • 开胸入路患者平均总索引住院成本为204,107美元/例。
  • 开胸入路较胸骨正中切开组降低21.6%(P < .001),每例节省56,385美元。
  • 几乎在所有成本类别中,开胸入路植入的成本均更低。

关键数值与推荐

  • 平均总索引住院成本:开胸入路204,107美元/例。
  • 成本降低幅度:21.6%(P < .001)。
  • 每例节省:56,385美元。

临床怎么用

  • 在考虑HVAD植入经济性时,开胸入路可能较传统胸骨正中切开降低索引住院成本。

局限性

  • Medicare队列假定以传统胸骨正中切开为主,非随机对照。
  • 成本比较基于同期Medicare数据而非直接对照试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Less invasive techniques for left ventricular assist device implantation have been increasingly prevalent over past years and have been associated with improved clinical outcomes. The procedural economic impact of these techniques remains unknown. We sought to study and report economic outcomes associated with the thoracotomy implantation approach. METHODS: The LATERAL clinical trial evaluated the safety and efficacy of the thoracotomy approach for implantation of the HeartWare centrifugal-flow ventricular assist device system (HVAD). We collected UB-04 forms in parallel to the trial, allowing analysis of index hospitalization costs. All charges were converted to costs using hospital-specific cost-to-charge ratios and were subsequently compared with Medicare cost data for the same period (2015-2016). Because thoracotomy implants were off-label for all left ventricular assist devices during that period, the Medicare cohort was assumed to consist predominately of traditional sternotomy patients. RESULTS: Thoracotomy patients demonstrated decreased costs compared with sternotomy patients during the index hospitalization. Mean total index hospitalization costs for thoracotomy were $204,107 per patient, corresponding to 21.6% reduction (P < .001) and $56,385 savings per procedure compared with sternotomy. Across almost all cost categories, thoracotomy implants were less costly. CONCLUSIONS: In LATERAL, a clinical trial evaluating the safety and efficacy of the thoracotomy approach for HVAD, costs were lower than those reported in Medicare patient claims occurring over the same period. Because Medicare data can be presumed to consist of predominately sternotomy procedures, thoracotomy appears less expensive than traditional sternotomy.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Mokadam NA, McGee E, Wieselthaler G, et al. Cost of Thoracotomy Approach: An Analysis of the LATERAL Trial. Ann Thorac Surg. 2020. PMID: 32224242. doi:10.1016/j.athoracsur.2020.02.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。